BRP: The AI-Discovered Peptide That Targets the Brain’s Weight-Control Center Differently Than Ozempic

Stanford scientists used an AI algorithm to screen 20,000 human proteins and found a 12-amino-acid peptide called BRP that suppresses appetite by targeting the hypothalamus, not the GLP-1 receptor, raising the possibility of a precision obesity treatment with a cleaner side-effect profile.

Presented By Our Partners

When semaglutide launched as a blockbuster obesity drug, it reshaped how medicine thinks about appetite regulation. But Ozempic’s success also revealed a persistent clinical reality: its broad mechanism of action, reaching receptors in the brain, gut, pancreas, and other tissues simultaneously, produces the weight loss most patients want alongside the side effects many cannot tolerate. Nausea, vomiting, constipation, and muscle loss have driven significant dropout rates in real-world settings, even as prescriptions continue to climb.

Now a team of researchers from Stanford Medicine, working with collaborators at UC Berkeley, the University of Minnesota, and the University of British Columbia, has identified a naturally occurring human peptide called BRP that appears to suppress appetite through a fundamentally different route: by acting specifically in the hypothalamus, the brain region that serves as the master regulator of energy balance and hunger, rather than through the GLP-1 receptor circuit that semaglutide targets.

Their findings, published in Nature and led by senior author Katrin Svensson, PhD, an assistant professor of pathology at Stanford Medicine, suggest that BRP could become the basis for a next-generation obesity treatment targeting metabolic control at a cellular and neurological level not previously accessible to any approved therapy. The study, authored by Laetitia Coassolo and colleagues (DOI: 10.1038/s41586-025-08683-y), has drawn renewed attention in November 2026 as the clinical development pathway accelerates.

The Algorithm That Found the Hormone

The discovery of BRP was not accidental. It was the product of a computational approach the research team built from scratch to solve a specific biological problem: the fact that most of the hormones the human body uses to regulate appetite, digestion, and metabolism are not secreted as finished active molecules. They are made first as larger, inactive precursor proteins called prohormones, which are then cleaved by enzymes into the smaller, biologically active peptide fragments that actually do the work.

GLP-1 itself is generated this way: the enzyme prohormone convertase 1/3, commonly abbreviated as PC1/3, clips it from the larger protein proglucagon. And PC1/3 has an established link to human obesity: mutations that impair this enzyme cause severe early-onset obesity, suggesting that the hormones it generates are collectively critical for body weight regulation. That made PC1/3 a logical starting point for a systematic search.

Svensson’s team built what they called the Peptide Predictor, a computer algorithm that scanned all roughly 20,000 human protein-coding genes for sequences where PC1/3 was likely to cut. The algorithm applied two filters designed to identify hormone candidates: the protein had to be secreted outside of cells, as most hormones are, and it had to contain at least four potential cut sites for the enzyme.

The result was a computational library of 373 candidate prohormones, which the Peptide Predictor estimated could yield 2,683 distinct peptide fragments. From this large pool, Svensson and lead researcher Laetitia Coassolo, PhD, a senior research scientist at Stanford Medicine, selected candidates most likely to influence brain activity and tested 100 of them, including GLP-1 as a benchmark, on cultured nerve cells.

The measuring stick was neuronal activation. GLP-1 stimulated neurons at roughly three times the control rate. BRP, a 12-amino-acid peptide cleaved from a previously little-studied protein called BRINP2 (BMP/retinoic acid inducible neural specific 2), activated neurons at approximately 10 times the control rate, more than three times as potent as GLP-1 on that measure. BRP was the standout signal in the entire screen.

A Hormone No One Was Looking For

BRINP2, the protein from which BRP derives its name, had been identified before but was not associated with appetite regulation or metabolic control. The cleavage of BRINP2 into the BRP fragment was not documented in the scientific literature prior to this work. In that sense, BRP is a genuinely novel discovery: a naturally occurring human hormone that the body produces but that science had not previously connected to energy balance.

What makes BRP mechanistically significant is where the peptide acts. While semaglutide’s receptors are distributed across multiple organ systems simultaneously, the research team found that BRP appears to act specifically in the hypothalamus. It influences overlapping but distinct populations of neurons from those targeted by GLP-1, and it activates different metabolic signaling pathways rather than simply reproducing the GLP-1 receptor effect through a different molecule.

“Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight,” Svensson told Stanford Medicine’s news office. The statement acknowledges semaglutide’s established efficacy while pointing to BRP’s potential to achieve similar outcomes through a narrower, more precisely targeted mechanism.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The receptor or receptors that BRP binds remain unidentified, which the team acknowledges as one of the most important open questions in this research. Without knowing the receptor, the full scope of BRP’s biological activity in the human body cannot be predicted. Identifying it is listed as a top scientific priority for continued work.

What the Animal Data Show

The preclinical data are striking. In lean mice and minipigs, a single intramuscular injection of BRP given before a feeding period reduced food intake by up to 50 percent in the following hour compared with expected consumption. In obese mice receiving daily BRP injections over 14 days, treated animals lost an average of approximately three grams of body weight while control animals gained approximately three grams, a swing of roughly six grams over two weeks. The team reports that nearly all the weight lost in the BRP-treated animals came from fat tissue rather than lean mass.

That muscle-preservation finding, if it holds in humans, would address one of the more clinically significant concerns about current GLP-1 receptor agonists. Multiple real-world analyses of semaglutide have noted that a meaningful proportion of weight lost during treatment comes from lean tissue rather than fat alone, a metabolic outcome with long-term implications for resting metabolic rate, physical function, and fall risk in older adults. BRP’s animal data suggest a different body composition profile, though the mechanism for why fat rather than muscle is preferentially mobilized is not yet understood.

The treated animals also showed improvements in glucose tolerance and insulin sensitivity, the metabolic markers most directly relevant to metabolic syndrome and type 2 diabetes risk.

On the safety monitoring measures available in animals, the BRP cohort showed no significant differences from controls in movement patterns, water intake, anxiety-related behavior, or fecal output. The fecal output finding is worth noting specifically: constipation is one of the most commonly reported and treatment-limiting side effects of GLP-1 receptor agonists, affecting a significant fraction of patients on semaglutide. BRP produced no such effect in mice or pigs. Nausea, the most common early-treatment complaint with semaglutide, cannot be reliably assessed in animal models, so whether BRP will prove easier to tolerate in that regard remains unknown until human testing is underway.

No Head-to-Head Comparison Exists Yet

It is important to note that this research did not pit BRP directly against semaglutide in a controlled experimental comparison. The “advantage” framing rests on the mechanistic difference (hypothalamus-specific rather than broadly distributed), the body composition data (mostly fat lost), and the safety monitoring results in animals, not on a randomized head-to-head comparison of the two therapies in the same subjects.

What exists now is a clear scientific rationale for why a hypothalamus-specific peptide might produce a cleaner side-effect profile than a broadly distributed receptor agonist, backed by animal data showing the expected direction of effects on appetite, body weight, body composition, and metabolic markers. That is a compelling foundation for clinical development, but the translation to human efficacy and safety remains to be demonstrated.

The research team has been careful to frame BRP’s potential relative to semaglutide in terms of what it could offer if human trials succeed, not what has been proven to date. Preclinical obesity research has a long and humbling history of promising results in rodents that have not transferred to humans, and BRP should be understood in that context.

From Lab to Clinic: The Development Pathway

The research team is moving toward clinical development with intention. Svensson and Coassolo are named inventors on patents covering the use of BRP peptides for metabolic disorders. Svensson has also co-founded Merrifield Therapeutics specifically to advance BRP toward human clinical trials, bringing the discovery directly into a commercial development pipeline with the full involvement of the scientists who made the original finding.

One pharmacological challenge the team openly acknowledges is peptide stability. Like most naturally occurring peptides, BRP breaks down quickly in circulation, which would require frequent injections in its current form. That would be a commercial and practical disadvantage compared to the weekly or twice-monthly injection schedules that have made semaglutide and tirzepatide relatively convenient for patients. Merrifield Therapeutics and the academic team are working on longer-acting chemical modifications to extend BRP’s half-life to something clinically workable, a standard step in peptide drug development.

The research was funded by the National Institutes of Health (grants R01DK125260, P30DK116074, K99AR081618, and GM113854), Stanford’s SPARK program for translational research, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, and the Carlsberg Foundation. That funding stack reflects both the scientific confidence the university saw in this work at an early stage and the institutional support now behind its development path.

What BRP Reveals About the Undiscovered Hormone Landscape

Perhaps as significant as BRP itself is what the Peptide Predictor methodology reveals about how much of the body’s own regulatory biology remains to be discovered. The algorithm identified 2,683 potential peptides from 373 prohormones. BRP was one candidate in a computational library of thousands, identified by a relatively efficient two-step process: computational filtering for secreted proteins with multiple PC1/3 cut sites, followed by neuronal activity testing in culture.

This approach is accessible and scalable. The same methodology the Svensson lab used could be applied systematically across the remaining candidates in the Peptide Predictor library. The human body may be producing dozens or hundreds of small peptide hormones that play roles in appetite regulation, inflammation, sleep, or other physiologically important processes that science has not yet identified because no one has looked for them in this systematic, AI-assisted way.

This reframing matters for anyone following the trajectory of AI in medicine. The GLP-1 drug class was discovered through decades of biological investigation into incretin hormones. BRP was found in a computational screen covering the entire human proteome in a fraction of that time. The implication is that the discovery rate for new metabolic targets could accelerate substantially as AI-assisted prohormone screening becomes a standard tool in the field, particularly as protein language models and structure prediction tools make it easier to rapidly characterize which of those 2,683 predicted peptides are likely to be active and in which tissues.

The Metabolic Health Stakes

Obesity is one of the leading drivers of what HD.ai identifies as the Four Shadows: the primary chronic disease threats that cut short both lifespan and healthspan. Excess visceral fat drives cardiovascular disease and metabolic dysfunction directly, and the metabolic dysregulation that accompanies obesity contributes meaningfully to cancer risk, neurodegenerative burden, and immune dysfunction. The GLP-1 receptor agonist revolution has been transformative precisely because effective treatment of obesity creates downstream protection across multiple disease categories simultaneously.

BRP, if it succeeds in human trials, could address the access and tolerability gaps that currently limit who benefits from that protection. If a hypothalamus-specific peptide produces meaningful weight loss with less nausea, less constipation, and better preservation of muscle mass, the pool of patients who can sustain treatment long enough to realize metabolic benefits would expand substantially. That is the actual clinical significance behind the mechanistic science: not just a different molecule, but potentially a different and larger set of patients who gain access to effective obesity medicine at all.

What This Means For You

BRP is not a treatment available today. It is a preclinical discovery with compelling animal data that is now moving toward clinical development through Merrifield Therapeutics. The path from impressive animal results to an approved human therapy requires years of safety and efficacy testing, dose-finding, and regulatory review, and many promising preclinical candidates do not complete that journey. That is not reason for skepticism about the underlying science, but it is reason for calibrated expectations about timing. A BRP-based therapy, if development proceeds smoothly, is likely at least several years from regulatory review.

What this research offers right now is a clear signal that the pipeline of obesity and metabolic disease treatments behind semaglutide and tirzepatide may be considerably richer than the GLP-1 receptor agonist category alone suggests. The Peptide Predictor approach found BRP in a library of thousands of candidates using a relatively efficient computational screen. That is not how drug discovery worked a decade ago, and it is evidence that AI-accelerated screening of native human biology is opening therapeutic territory that classical pharmacology had no systematic way to access.

If you are currently on a GLP-1 receptor agonist and tolerating it well, the emergence of BRP in development changes nothing about your treatment today. If you are among the patients who have tried and discontinued GLP-1 therapy due to side effects, or who have not found adequate access to it, BRP represents the kind of mechanistically distinct alternative the field has needed. The hypothalamus-specific mechanism is a genuine scientific differentiation from anything currently approved, and the muscle-preservation signal from animal data points in a direction that metabolic medicine has been trying to reach for years.

In the meantime, the best evidence for metabolic health continues to be what it has always been: whole-food nutrition that supports blood sugar stability, resistance training that builds and preserves muscle mass, adequate sleep for hormonal regulation, and the management of chronic stress that disrupts metabolic function. BRP may one day become a tool that makes those foundations easier for more people to build on. For now, it is the clearest signal yet that the biology of appetite regulation is far more complex, and far more pharmacologically accessible, than the GLP-1 story alone would suggest.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.

Keep Reading on Healthcare Discovery

• Longevity Escape Velocity, Explained Through Isomorphic Labs
• PNOĒ Portable Metabolic Analyzer: Clinical Indirect Calorimetry for Gyms and Clinics
• Mitochondrial Transplantation Enters Human Trials: How Moving Living Powerhouses Between Cells Is Rewriting Longevity Medicine